Roberta Di Fonte

Dr. Roberta Di Fonte

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 March 2019 in Scientific Reports
Verified
Journal Article
Open access
PDF file
Amalia AzzaritiAmalia Azzariti
Amalia Azzariti
RIRosa Maria Iacobazzi
Rosa Maria Iacobazzi
RFRoberta Di Fonte
Roberta Di Fonte
LPLetizia Porcelli
Letizia Porcelli
RGRoberto Gristina
Roberto Gristina
Eloisa SardellaEloisa Sardella
Eloisa Sardella
Over the past decade, cold atmospheric plasmas have shown promising application in cancer therapy. The therapeutic use of plasma-activated media is a topic addressed in an emerging field known as plasma pharmacy. In oncology, plasma-activated media are used to harness the therapeutic effects of oxidant species when they come in contact with cancer cells. Among several factors that contribute to the anticancer effect of plasma-activated liquid media (PALM), H2O2 and NO derivatives likely play a key role in the apoptotic pathway. Despite the significant amount of literature produced in recent years, a full understanding of the mechanisms by which PALM exert their activity against cancer cells is limited. In this paper, a sealed dielectric-barrier discharge was used to disentangle the effect of reactive nitrogen species (RNS) from that of reactive oxygen species (ROS) on cancer cells. Two cancers characterized by poor prognosis have been investigated: metastatic melanoma and pancreatic cancer. Both tumour models exposed to PALM rich in H2O2 showed a reduction in proliferation and an increase in calreticulin exposure and ATP release, suggesting the potential use of activated media as an inducer of immunogenic cell death via activation of the innate immune system.

7 March 2019 in Cancers
Verified
Journal Article
Open access
PDF file
LPLetizia Porcelli
Letizia Porcelli
Rosa Maria IacobazziRosa Maria Iacobazzi
Rosa Maria Iacobazzi
RFRoberta Di Fonte
Roberta Di Fonte
Simona Serrati'Simona Serrati'
Simona Serrati'
AIAngelica Intini
Angelica Intini
Nicola SilvestrisNicola Silvestris
Nicola Silvestris
Tumor–stroma interactions are of key importance for pancreatic ductal adenocarcinoma (PDAC) progression. Our aim was to investigate whether cancer associated fibroblasts (CAFs) and mast cells (MC) affected the sensitivity of PDAC cells to gemcitabine/nabpaclitaxel (GEM/NAB). For this purpose, the combination cytotoxicity and the effect on tumor invasion and angiogenesis were evaluated with or without a conditioned medium from the mast cell line HMC-1 (human mast cell line-1 cells) and CAFs. Beside the clinical outcome of a homogenous population of PDAC patients, receiving GEM/NAB, was correlated to the circulating levels of mast cell tryptase and to a panel of inflammatory and immunosuppressive cytokines. CAFs neither affected drugs’ cytotoxicity nor the inhibition of angiogenesis, but promoted tumor cell invasion. The MC instead, caused resistance to drugs by reducing apoptosis, by activating the TGF-β signalling and by promoting tumor invasion. Indeed, the inhibition of TβRI serine/threonine kinase activity by galunisertib restored drugs cytotoxicity. Moreover, MC induced the release of TGF-β1, and increased expression of PAR-2, ERK1/2 and Akt activation. Accordingly, TGF-β1, tryptase and other pro-inflammatory and immunosuppressive cytokines increased in the unresponsive patients. In conclusion, MC play a pivotal role in the resistance to GEM/NAB. A correlation between high level of circulating pro-inflammatory/ immunosuppressive cytokines and unresponsiveness was found in PDAC patients.

4 July 2019 in Cancers
Verified
Journal Article
Open access
PDF file
AAAntonella Argentiero
Antonella Argentiero
SSSimona De Summa
Simona De Summa
RFRoberta Di Fonte
Roberta Di Fonte
Rosa Maria IacobazziRosa Maria Iacobazzi
Rosa Maria Iacobazzi
LPLetizia Porcelli
Letizia Porcelli
Antonio Giovanni SolimandoAntonio Giovanni Solimando
Antonio Giovanni Solimando
Over the past several years there has been much debate with regards to the prognostic and clinical significance of pancreatic ductal adenocarcinoma (PDAC) with lymph nodes metastasis. The PDAC gene expression knowledge and the biologic alterations underlying the lymph node involvement convey a clinical implication in dealing with the theranostic window. To this end, we provide an original bioinformatic dissection of the gene expression differences of PDAC according to the nodal involvement from a large public available dataset. Comprehensive transcriptomic analysis from 143 RNA-seq patient’s derived samples indicated that WNT increased activation and a peculiar immune microenvironment identify subjects with nodal involvement. In frame of this thinking, we validated the WNT pathway role in increasing the likelihood of lymphatic dissemination in vitro. Moreover, we demonstrated for the first time in a PDAC model the potential therapeutic window that XAV-939—a specific WNT pathway inhibitor—has in re-educating a tumor-permissive immune system. Finally, we outline the potential implication on bystander molecular drivers exerted by WNT molecular inhibition, providing a picture of the proteomic oncogenic landscape changes elicited by XAV-939 on PDAC cells and their clinical implication. Our findings hold the promise to identify novel immune-based therapeutic strategies targeting WNT to enhance PDAC cytotoxicity and restore anti-PDAC immunity in node-positive disease.

1 August 2017 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
RIRosa Maria Iacobazzi
Rosa Maria Iacobazzi
LPLetizia Porcelli
Letizia Porcelli
ALAngela Assunta Lopedota
Angela Assunta Lopedota
VLValentino Laquintana
Valentino Laquintana
Antonio LopalcoAntonio Lopalco
Antonio Lopalco
Nunzio DenoraNunzio Denora
Nunzio Denora

1 February 2020 in Clinical Immunology
Verified
Journal Article
Closed access
AVAndrea Vecchione
Andrea Vecchione
RFRoberta Di Fonte
Roberta Di Fonte
JGJolanda Gerosa
Jolanda Gerosa
TJTatiana Jofra
Tatiana Jofra
MCMaria Pia Cicalese
Maria Pia Cicalese
GFGeorgia Fousteri
Georgia Fousteri

21 December 2021 in Cancers
Verified
Journal Article
Open access
PDF file
Rosa Maria IacobazziRosa Maria Iacobazzi
Rosa Maria Iacobazzi
Ilaria ArduinoIlaria Arduino
Ilaria Arduino
RFRoberta Di Fonte
Roberta Di Fonte
Angela LopedotaAngela Lopedota
Angela Lopedota
Simona Serrati'Simona Serrati'
Simona Serrati'
Amalia AzzaritiAmalia Azzariti
Amalia Azzariti
Pancreatic ductal adenocarcinoma (PDAC) represents a great challenge to the successful delivery of the anticancer drugs. The intrinsic characteristics of the PDAC microenvironment and drugs resistance make it suitable for therapeutic approaches with stimulus-responsive drug delivery systems (DDSs), such as pH, within the tumor microenvironment (TME). Moreover, the high expression of uPAR in PDAC can be exploited for a drug receptor-mediated active targeting strategy. Here, a pH-responsive and uPAR-targeted Gemcitabine (Gem) DDS, consisting of polymeric micelles (Gem@TpHResMic), was formulated by microfluidic technique to obtain a preparation characterized by a narrow size distribution, good colloidal stability, and high drug-encapsulation efficiency (EE%). The Gem@TpHResMic was able to perform a controlled Gem release in an acidic environment and to selectively target uPAR-expressing tumor cells. The Gem@TpHResMic displayed relevant cellular internalization and greater antitumor properties than free Gem in 2D and 3D models of pancreatic cancer, by generating massive damage to DNA, in terms of H2AX phosphorylation and apoptosis induction. Further investigation into the physiological model of PDAC, obtained by a co-culture of tumor spheroids and cancer-associated fibroblast (CAF), highlighted that the micellar system enhanced the antitumor potential of Gem, and was demonstrated to overcome the TME-dependent drug resistance. In vivo investigation is warranted to consider this new DDS as a new approach to overcome drug resistance in PDAC.